BEAM insider trading
HealthcareBeam Therapeutics Inc.: insider trade history from SEC Form 4 filings.
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Company website: beamtx.com
BEAM insider activity at a glance
FilingIQ tracks 456 insider transactions for BEAM in filings since Feb 11, 2020. The most recent transaction is dated Oct 1, 2026.
Across the full history, 0 open-market purchases
and 247 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on BEAM insider trades is 57.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest BEAM Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding BEAM
Frequently asked
- How many insider trades does FilingIQ track for BEAM?
- FilingIQ tracks 456 Form 4 insider transactions for BEAM (Beam Therapeutics Inc.), covering filings from Feb 11, 2020 onwards. 3 of those are dated within the last 90 days.
- Are BEAM insiders net buyers or net sellers?
- Across the full Form 4 history for BEAM, 0 transactions (0%) were open-market purchases and 247 (54%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does BEAM insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is BEAM in?
- Beam Therapeutics Inc. (BEAM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.78B.
Methodology & sources
Every BEAM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.